Molecular Pharmacology Stock Fundamentals
| MLPH Stock | USD 0.0001 0.00 0.00% |
Molecular Pharmacology fundamentals help investors to digest information that contributes to Molecular Pharmacology's financial success or failures. It also enables traders to predict the movement of Molecular Pink Sheet. The fundamental analysis module provides a way to measure Molecular Pharmacology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Pharmacology pink sheet.
Molecular |
Molecular Pharmacology Company Current Valuation Analysis
Molecular Pharmacology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Molecular Pharmacology Current Valuation | 221.59 K |
Most of Molecular Pharmacology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Pharmacology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Molecular Pharmacology has a Current Valuation of 221.59 K. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.0% higher than that of the company.
Molecular Pharmacology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Molecular Pharmacology's current stock value. Our valuation model uses many indicators to compare Molecular Pharmacology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Molecular Pharmacology competition to find correlations between indicators driving Molecular Pharmacology's intrinsic value. More Info.Molecular Pharmacology is rated below average in return on asset category among its peers. It also is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Molecular Pharmacology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Molecular Pharmacology's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Molecular Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Pharmacology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Molecular Pharmacology could also be used in its relative valuation, which is a method of valuing Molecular Pharmacology by comparing valuation metrics of similar companies.Molecular Pharmacology is currently under evaluation in current valuation category among its peers.
Molecular Fundamentals
| Return On Asset | -5.69 | |||
| Current Valuation | 221.59 K | |||
| Shares Outstanding | 111.55 M | |||
| Price To Earning | (0.80) X | |||
| EBITDA | (98.11 K) | |||
| Net Income | (116.93 K) | |||
| Cash And Equivalents | 1.52 K | |||
| Total Debt | 175.33 K | |||
| Current Ratio | 0.28 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.41 K) | |||
| Beta | 42.97 | |||
| Market Capitalization | 26.77 K | |||
| Total Asset | 8.97 K | |||
| Working Capital | (2.1 M) | |||
| Current Asset | 9 K | |||
| Current Liabilities | 2.11 M | |||
| Net Asset | 8.97 K |
About Molecular Pharmacology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Molecular Pharmacology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Pharmacology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Pharmacology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. Molecular Pharmacology Limited is a subsidiary of PharmaNet Group Limited. Molecular Pharmacology is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.